Profil
Shahid Nimjee is the founder and Chief Medical Officer of Basking Biosciences, Inc. which is founded in 2019.
Postes actifs de Shahid Nimjee
| Sociétés | Poste | Début |
|---|---|---|
Basking Biosciences, Inc.
 Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Fondateur | 01/01/2019 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Basking Biosciences, Inc.
Basking Biosciences, Inc. BiotechnologyHealth Technology Basking Biosciences, Inc. is a clinical-stage company that aims to solve the biggest need in ischemic stroke therapy. The company is based in Columbus, OH. The company is developing a first-in-class RNA aptamer targeting von Willebrand factor (vWF), an important structural component of blood clots and driver of the clotting process. Basking is also developing a complementary rapid-acting reversal oligonucleotide capable of quickly neutralizing the pharmacological activity of the RNA aptamer. The company has successfully completed a phase 1 single-ascending dose safety study and is initiating a phase 2 clinical proof-of-concept study in patients suffering from an acute ischemic stroke. The ultimate goal is to extend the therapeutic window for thrombolysis compared to currently approved therapies. Basking Biosciences was founded in 2019 by Shahid Nimjee, Bruce A. Sullenger, and Richard J. Shea has been the CEO of the company since 2019. | Health Technology |
